Turtle Beach (HEAR) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Jacques Cornet - PartnerCris Keirn - CEOMark Weinswig - CFO Conference Call Participants Anthony Stoss - AnalystSean McGowan - MD & Senior Research AnalystMartin Yang - Senior AnalystNone - Analyst Operator and welcome to Turtle Beach Q1 twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a remin ...

Turtle Beach (HEAR) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Jacques Cornet - PartnerCris Keirn - CEOMark Weinswig - CFO Conference Call Participants Anthony Stoss - AnalystSean McGowan - MD & Senior Research AnalystMartin Yang - Senior AnalystNone - Analyst Operator and welcome to Turtle Beach Q1 twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a remin ...

Farmer Bros. (FARM) Q3 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants John Moore - CEO & PresidentVance Fisher - Chief Financial Officer Conference Call Participants Eric Des Lauriers - Research AnalystGerry Sweeney - Managing Director, Senior Research Analyst Operator Good afternoon and welcome to the Farmer Brothers Third Quarter Fiscal twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being recorded. Today, ...

Financial Data and Key Metrics Changes - System wide sales for Q1 2025 were $132.6 million, up 5% compared to Q1 2024, indicating resilience in the current economic environment [10] - Revenue from continuing operations increased by 7% to $13.1 million compared to $12.2 million in Q1 2024 [29] - Adjusted EBITDA from continuing operations was $46,000, a significant decrease from $425,000 in Q1 2024 [10][29] - Net loss from continuing operations was $506,000, compared to a loss of $399,000 in Q1 2024 [30] Business Line Data and Key Metrics Changes - Comp sales for all clinics open for at least 13 months were up 3% for Q1 2025 and increased to 4% in March 2025 [10][24] - Comp sales for mature clinics (open for at least 48 months) were down 2% [24][82] - The company refranchised two corporate clinics and opened five franchise clinics during Q1 2025, with a total of 969 clinics, of which 847 (87%) are franchise clinics [25][26] Market Data and Key Metrics Changes - The company expects system wide sales for 2025 to be between $550 million and $570 million, compared to $530.3 million in 2024 [32] - Comp sales for clinics open for 13 months or more are expected to be in the mid-single digits for 2025 [32] Company Strategy and Development Direction - The company aims to become a pure play franchisor, with 93% of corporate clinics under Letters of Intent (LOIs) for refranchising [12][51] - The strategy includes dynamic revenue management, strengthening digital marketing, and enhancing patient-facing technology [12][19][22] - The company is focusing on pain-centric messaging to attract new patients, as 74% of new patients cite pain as a reason for visiting [35][39] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a dynamic consumer environment and is closely monitoring the situation while pushing ahead with the transition plan [11] - The company anticipates a transformative financial impact as clinics shift from company-owned to franchise clinics, leading to increased franchise royalties and fees [34] - Economic headwinds, inflation, and volatile consumer sentiment are expected to impact the beginning of 2025, but the company remains optimistic about future profitability [34] Other Important Information - The company has welcomed new executives to enhance legal strategy and operations, aiming to improve clinic quality and economics [41] - The Joint has been recognized as one of the fastest-growing franchises and ranked in the Franchise 500 [41] Q&A Session Summary Question: New patient ad metrics and retention trends - Management noted that new patient volumes have been affected by overall consumer sentiment, but retention rates remain stable [44][46] Question: Metrics on profitability and overhead reduction - Management is not ready to provide specific metrics but expects profitability to improve as G&A expenses are reduced [47][49] Question: Timeline for refranchising process completion - Management intends to exit 2025 as a pure play franchisor and hopes to accelerate the refranchising process [51] Question: Comp sales performance and dynamics - Management did not disclose April comp sales but confirmed a return to 4% in March [57] - Franchise clinic comp performance mirrors consolidated comp, with corporate clinic comp trailing slightly [59] Question: Dynamic pricing opportunities - Management is exploring various pricing models, with potential for double-digit impacts on system wide sales [61] Question: Selling and marketing expenses normalization - Management expects selling and marketing expenses to normalize by Q3 2025 after a dual agency transition [68] Question: Strategies for mature clinics to improve comp sales - Management is implementing operational strategies and marketing tactics aimed at strengthening existing clinics [83][85]

Financial Data and Key Metrics Changes - First quarter revenue increased by 14% year over year to $63.9 million, driven by the full quarter contribution from the PDP acquisition [4][14] - Adjusted EBITDA rose to $4.1 million, up 180% from $1.4 million a year ago, indicating strong operating leverage [4][16] - Gross margins improved by 470 basis points year over year to 36.6% [5][14] - Operating expenses were $21.8 million, representing 34% of revenue compared to 42% in the prior year [15] Business Line Data and Key Metrics Changes - The U.S. gaming accessories market experienced a 16% year over year decline in Q1, impacting overall market performance [5][27] - Despite the market decline, the company achieved revenue growth due to the PDP acquisition and improved product offerings [4][5] Market Data and Key Metrics Changes - The broader gaming accessories market is projected to decline by 10% to 12% for the full year 2025, influenced by factors such as the delayed release of Grand Theft Auto VI and tariff impacts [28][41] - The company anticipates a gradual improvement in market conditions throughout 2025, particularly with the upcoming launch of the Nintendo Switch 2 [11][19] Company Strategy and Development Direction - The company is focusing on expanding its gaming accessories portfolio and capitalizing on industry growth drivers, including new product launches [12][22] - A new share repurchase program of up to $75 million over the next two years has been authorized, reflecting confidence in the company's future [13][18] - The company is actively managing supply chain diversification to mitigate tariff impacts, with less than 10% of U.S. supply produced in China after Q1 [9][60] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by tariffs and the evolving economic landscape but expressed confidence in navigating these issues with minimal long-term effects [8][22] - The company remains optimistic about returning to robust growth in 2026 and beyond, driven by a growing gamer base and new game releases [11][19] Other Important Information - The company generated over $40 million in cash flow from operations during Q1, marking one of the highest cash flow-generating quarters in its history [17] - The company is implementing pricing adjustments to mitigate tariff impacts, which have already been factored into the revised guidance [54][56] Q&A Session Summary Question: Impact of GTA VI delay on revenue reduction - Management indicated that the revenue reduction is a combination of factors, including the GTA VI delay and broader market challenges, with the accessories market down 16% in Q1 [25][26] Question: Expectations for gross margins in upcoming quarters - Gross margins are expected to be in the low 30s for Q2, with potential recovery in Q3 and Q4 as the company adjusts to market conditions [31][33] Question: Further cost controls in light of revised guidance - The company is actively pursuing cost synergies from the PDP acquisition and is identifying additional opportunities for cost reductions [34][35] Question: Flexibility to rebound if market conditions improve - Management stated that they are well-prepared to respond to any positive changes in market conditions, with a strong inventory position [41][42] Question: Tariff assumptions for Vietnam in projections - Current guidance reflects existing tariff conditions, and the company is ready to adjust its plans based on any changes in the tariff landscape [46][48] Question: Pricing adjustments due to tariffs - Pricing adjustments have been communicated to partners and are included in the revised guidance, with some products absorbing the tariff impact entirely [54][56] Question: Transition to Vietnam and competitive advantage - The company has been diversifying its supply chain for years and was able to quickly shift production to mitigate tariff impacts, which may provide a competitive advantage [58][60]

News (NWS) Q3 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Welcome to the News Corp's Third Quarter Fiscal twenty twenty five earnings conference call. Today's conference is being recorded. Media will be allowed on a listen only basis. At this time, I'd like to turn the conference over to Michael Floren, senior vice president and head of investor relations. Please go ahead. Speaker1 Thank you very much, operator. Hello, everyone, and welcome to News Corp's fiscal third quarter two thousand twenty fi ...

Financial Data and Key Metrics Changes - System wide sales for Q1 2025 were $132.6 million, up 5% compared to Q1 2024, indicating resilience in the current economic environment [10] - Revenue from continuing operations increased by 7% to $13.1 million from $12.2 million in Q1 2024 [27] - Adjusted EBITDA from continuing operations was $46,000, a significant decrease from $425,000 in Q1 2024 [10][29] - Net loss from continuing operations was $506,000, compared to a loss of $399,000 in Q1 2024 [29] Business Line Data and Key Metrics Changes - Comp sales for all clinics open for at least 13 months were up 3% for Q1 2025 and increased to 4% in March 2025 [10][23] - Comp sales for mature clinics (open for at least 48 months) were down 2% [23] - The company refranchised two corporate clinics and opened five franchise clinics during Q1 2025, with a total of 969 clinics, of which 847 (87%) are franchise clinics [25] Market Data and Key Metrics Changes - The company is experiencing a dynamic consumer environment, with consumer sentiment affecting new patient volumes [11][43] - The company anticipates system wide sales for 2025 to be between $550 million and $570 million, compared to $530.3 million in 2024 [31] Company Strategy and Development Direction - The company aims to become a pure play franchisor, with 93% of corporate clinics under Letters of Intent (LOIs) for refranchising [12][49] - The focus is on strengthening core operations, reigniting growth, and improving profitability through dynamic revenue management and enhanced digital marketing strategies [12][18] - The company plans to launch a new marketing campaign centered around pain relief in the second half of the year [36] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the impact of economic headwinds, inflation, and consumer sentiment on operations but remains optimistic about transitioning to a franchise model [33] - The company expects to see a transformative financial impact as corporate clinics transition to franchise royalties and fees, leading to increased profitability [33] Other Important Information - The company has welcomed new executives to enhance legal strategy and patient experience [39] - The Joint has been recognized as one of the fastest-growing franchises and ranked 37th in the Franchise 500 by Entrepreneur Magazine [40] Q&A Session Summary Question: New patient ad metrics and retention trends - Management noted that new patient volumes have been affected by consumer sentiment, but retention rates remain stable [42][44] Question: Metrics on profitability and overhead reduction - Management is not ready to provide specific metrics but expects profitability to improve as G&A expenses are reduced [45][47] Question: Timeline for refranchising process completion - Management intends to exit 2025 as a pure play franchisor and hopes to accelerate the refranchising process [49] Question: Comp sales performance and strategies for mature clinics - Comp sales for mature clinics have been consistent, and operational strategies will be geared towards strengthening these clinics [80][81] Question: Dynamic pricing impact - Management is exploring various pricing models and anticipates that pricing adjustments could significantly impact total system wide sales [60][62] Question: Selling and marketing expenses normalization - Management expects selling and marketing expenses to normalize by Q3 2025 as the transition to a single marketing agency is completed [66] Question: Cost of the franchisee spring convention - The cost of the convention was lower than previous years, impacting the sales and marketing line [75][76]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 16.5% to $324 million in the first quarter, driven by an increase in the number of clients and covered lives compared to the previous year [17] - Adjusted EBITDA grew 15% to $58 million, with an adjusted EBITDA margin of 17.8%, slightly down from the previous year [24][25] - Net income was $15.1 million or $0.17 per diluted share, compared to $16.9 million or $0.17 per share in the prior year [25] Business Line Data and Key Metrics Changes - Fertility revenue increased by 22% to $206 million, while pharmacy revenue grew by 9% to $118 million [22] - ART cycles reached a record high of 16,160, reflecting a 9% growth year-over-year [21] Market Data and Key Metrics Changes - The CDC reported record low birth rates for women aged 25 and younger, while rates for women aged 30 to 44 increased, indicating a shift in family planning trends [8][9] - More than 51% of all births in the U.S. now come from women aged 30 or older, highlighting the increasing need for fertility and maternity services [10] Company Strategy and Development Direction - The company is focused on expanding its product portfolio and enhancing member experience, particularly in women's health and family building [6][11] - The company aims to deepen relationships with existing clients, with 20% to 25% of the base typically taking additional services [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the current engagement levels and the pipeline for new clients, despite some macroeconomic uncertainties [12][13] - The company raised its full-year revenue guidance to between $1.185 billion and $1.235 billion, reflecting growth of 1.5% to 5.8% [29] Other Important Information - The company generated nearly $50 million in operating cash flow, nearly double the prior year period [25] - Total working capital as of March 31 was $331 million, with $256 million in cash and no debt [27] Q&A Session Summary Question: Inquiry about historical seasonality of cycles per utilizer - Management indicated that the guidance reflects uncertainty rather than a change in normal seasonality [32] Question: Drivers of gross margin expansion - Management noted that last year's revenue shortfall affected margins, and they expect gross margin expansion for the full year compared to 2024 [33][35] Question: Comments on the 2026 selling season and RFP processes - Management confirmed that they are not seeing a slowdown in RFP activities and are targeting to add at least 1 million new lives each year [40][43] Question: Impact of tariffs on costs - Management stated that existing tariffs have not significantly impacted costs, and they have flexibility in arrangements with clients to mitigate potential increases [54] Question: Pricing benefits in ART cycles - Management clarified that growth is primarily driven by engagement and consumption rather than pricing [69]

Financial Data and Key Metrics Changes - First quarter revenue grew 16.5% to $324 million, primarily due to an increase in the number of clients and covered lives compared to the previous year [15] - Adjusted EBITDA increased by 15% to $58 million, with an adjusted EBITDA margin of 17.8%, slightly down from the previous year [22][28] - Net income was $15.1 million or $0.17 per diluted share, compared to $16.9 million or $0.17 per share in the prior year [22] Business Line Data and Key Metrics Changes - Fertility revenue increased 22% to $206 million, while pharmacy revenue grew 9% to $118 million [20] - ART cycles reached a record high of 16,160, reflecting a 9% growth year-over-year [19] Market Data and Key Metrics Changes - The CDC reported record low birth rates for women aged 25 and younger, while rates for women aged 30 to 44 continue to rise, indicating a shift in family planning trends [6][7] - Over 51% of all births in the U.S. now come from women aged 30 or older, highlighting the increasing need for fertility and maternity solutions [8] Company Strategy and Development Direction - The company is focusing on expanding its product portfolio and enhancing member experience, particularly in women's health and family building [5][9] - New services in maternity, postpartum, and menopause are expected to contribute up to 10% of revenue by 2028, although significant contributions are not anticipated in the near term [13][14] Management's Comments on Operating Environment and Future Outlook - Management raised full-year guidance, projecting revenue between $1.185 billion and $1.235 billion, reflecting growth of 1.5% to 5.8% [27] - The company expects continued member engagement at historical levels, despite potential variability in activity and treatments [25] Other Important Information - The company generated nearly $50 million in operating cash flow in the first quarter, nearly double the prior year period [23] - Total working capital as of March 31 was $331 million, with $256 million in cash and no debt [24] Q&A Session Summary Question: Historical seasonality of cycles per utilizer - Management indicated that guidance reflects uncertainty rather than a change in normal seasonality [30] Question: Drivers of gross margin expansion - Management noted that last year's revenue shortfall affected margins, and while they expect gross margin expansion for the full year, investments may impact margins [31][33] Question: 2026 selling season and RFP process - Management confirmed that they are not seeing a slowdown in RFP activities and are targeting to add at least 1 million new lives each year [38][43] Question: Incremental adjusted EBITDA margin - Management explained that the lower margin is due to investments in platform and product expansion, which are expected to impact the P&L this year [44] Question: Interest in new modules - The menopause product is seeing higher engagement due to a larger addressable audience compared to maternity products [47] Question: Impact of tariffs on costs - Management stated that existing tariffs have not significantly impacted costs, and potential tariffs on pharmaceuticals are not expected to affect their operations [53] Question: Pricing benefits in ART cycles - Management clarified that growth is driven by engagement and activity rather than pricing [68]

TOMI Environmental Solutions (TOMZ) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Rosalyn Christian - Account ManagerHalden Shane - Chairman & CEOElissa Shane - COO & Director Conference Call Participants None - Analyst Operator Greetings. Welcome to the TOMI Environmental Solutions Inc. First Quarter two thousand twenty five Financial Results Conference Call. Please note this conference is being recorded. I will now turn the conference over to your host, Rosalynn Christian from IMS In ...